Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Oxidative Medicine and Cellular Longevity, 2017 , 8416763
SG has also been analyzed in 62 patients with refractory SCLC included in the IMMU-132-01 phase I-II trial, showing an ORR of 17.7%, a median PFS of 3.7 months and a median OS of 7.1 months [48,92]
These conclusions came from the observation of unexpected liver injury/hepatotoxicity, often as case reports, in patients clinically assessed as being malnourished [73, 78,79,80,81]
ASL is funded by the National Institutes of Health grant 5T32DK007135-46
MCCM Glutathione
Al-Temimi AA, Al-Mossawi AE, Al-Hilifi SA, Korma SA, Esatbeyoglu T, Rocha JM, Agarwal V
US$ 29.92
US$ 25.44
US$ 26.71
US$ 27.25
US$ 22.99
